Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEXEVA vs LUVOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder,Vasomotor symptoms associated with menopause
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Premenstrual dysphoric disorder (PMDD),Bulimia nervosa,Post-traumatic stress disorder (PTSD)
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Extensively metabolized by CYP2D6; minor pathways include CYP3A4; undergoes oxidative and conjugation reactions.
Primarily hepatic via CYP1A2; minor pathways via CYP2D6; active metabolites minimal.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
98% bound to albumin and α1-acid glycoprotein
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
20-30 L/kg; large Vd indicates extensive tissue distribution
The apparent volume of distribution is about 4.7 L/kg, indicating extensive extravascular distribution and tissue binding, which contributes to its long half-life.
Oral: 50-80% (first-pass metabolism)
Oral bioavailability is approximately 53% after a single dose, with no significant food effect. Bioavailability may be higher under steady-state conditions due to saturation of first-pass metabolism.
Creatinine clearance (Cr Cl) 30-59 m L/min: initially 10 mg once daily, maximum 40 mg once daily. Cr Cl < 30 m L/min or hemodialysis: initially 10 mg once daily, maximum 30 mg once daily.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥20 m L/min). Avoid use in severe renal impairment (Cr Cl <20 m L/min) due to lack of data.
Child-Pugh Class B or C: initially 10 mg once daily, maximum 30 mg once daily. Child-Pugh Class A: no adjustment recommended.
Child-Pugh Class A: no dose adjustment; Child-Pugh Class B: reduce dose by 50% (start 25 mg/day, titrate cautiously); Child-Pugh Class C: contraindicated.
Not FDA-approved for patients < 18 years; use not recommended due to increased risk of suicidal thoughts and behaviors.
Children (8-17 years): start 25 mg orally once daily at bedtime; increase by 25 mg increments every 4-7 days to target dose; for OCD: 25-200 mg/day; maximum 200 mg/day. Weight not routinely used; dosing based on age and response.
Initial dose 10 mg orally once daily; maximum 40 mg once daily. Elderly patients may have increased plasma concentrations and require slower titration.
Start 25 mg orally once daily at bedtime; titrate slowly (increases of 25 mg every 1-2 weeks); usual maximum 200 mg/day due to increased sensitivity and risk of hyponatremia.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in children, adolescents, and young adults,Serotonin syndrome,Discontinuation syndrome (withdrawal),Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Increased intraocular pressure,Hyponatremia,Abnormal bleeding,Sexual dysfunction,Bone fracture risk,Drug interactions with MAOIs and other serotonergic drugs
Suicidality risk in young patients,Serotonin syndrome,Activation of mania/hypomania,Seizure risk,Abnormal bleeding,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction,Discontinuation syndrome
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI,Concurrent use with tryptophan,Concurrent use with pimozide,Known hypersensitivity to paroxetine or any excipient
Concomitant use with MAOIs,Concomitant use with triptans,Hypersensitivity to fluvoxamine or any excipient,Pregnancy (relative)
Avoid grapefruit and grapefruit juice, as they can increase paroxetine levels and risk of toxicity. Alcohol may exacerbate CNS depression and should be limited. No other significant food interactions.
Avoid grapefruit juice as it inhibits CYP1A2 and can increase fluvoxamine serum concentrations, leading to toxicity. No other significant food interactions; however, taking with food may reduce GI upset.
PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, particularly ventricular septal defects, and an increased risk of omphalocele and craniosynostosis. Third trimester exposure may result in neonatal adaptation syndrome (e.g., respiratory distress, jitteriness, poor feeding, persistent crying) and rare cases of persistent pulmonary hypertension of the newborn (PPHN). The risk is dose-dependent and highest with doses above 25 mg/day.
First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hypertension of the newborn (PPHN) (OR 2.1). Second/third trimester: Late pregnancy exposure may increase risk of preterm birth, low birth weight, and neonatal adaptation syndrome (e.g., respiratory distress, feeding difficulties, irritability).
Paroxetine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-0.7. Though relative infant doses are low (typically <2% of maternal weight-adjusted dose), adverse effects such as irritability, poor feeding, and drowsiness have been reported. Caution is advised, particularly with high maternal doses; non-pharmacologic strategies or alternative antidepressants with more favorable lactation profiles may be preferred.
Fluvoxamine is excreted into breast milk; M/P ratio ranges from 0.29 to 0.59. Relative infant dose is approximately 1.7% of maternal weight-adjusted dose. Low risk of adverse effects in breastfed infants; monitor for drowsiness, poor feeding, and weight gain. AAP classifies as compatible with breastfeeding.
Pregnancy can alter paroxetine pharmacokinetics, leading to increased clearance and reduced plasma concentrations, particularly in the second and third trimesters. Dose adjustments (e.g., up to 1.5-2 times the pre-pregnancy dose) may be required to maintain therapeutic efficacy. However, higher doses increase fetal risk, so lowest effective dose should be used. Tapering or switching to a safer agent (e.g., fluoxetine or sertraline) is often considered. Postpartum, doses should be gradually reduced to pre-pregnancy levels to avoid toxicity.
Plasma levels of fluvoxamine may decrease during pregnancy due to increased volume of distribution and enhanced hepatic metabolism. Dose adjustment may be necessary; consider therapeutic drug monitoring to maintain efficacy. Usually, dose can be increased by 50-100% in third trimester, with gradual reduction postpartum to pre-pregnancy levels.
Pexeva (paroxetine mesylate) is an SSRI antidepressant. Due to its short half-life, abrupt discontinuation may cause withdrawal syndrome. It is also indicated for panic disorder, OCD, and social anxiety disorder. Use with caution in patients with narrow-angle glaucoma, as it can precipitate acute angle closure. Monitor for hyponatremia in elderly patients. Avoid concurrent use with MAOIs or other serotonergic agents due to risk of serotonin syndrome.
Luvox (fluvoxamine) is a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder (OCD) and social anxiety disorder. It has a short half-life (15-22 hours) and no active metabolites, making it suitable for patients with hepatic impairment. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic agents. Luvox is a potent inhibitor of CYP1A2, affecting metabolism of drugs like clozapine, olanzapine, theophylline, and tizanidine. Titrate slowly; start at 50 mg nightly and increase by 50 mg every 4-7 days to a max of 300 mg daily (divided for doses >100 mg). Discontinuation syndrome is common; taper gradually.
Take exactly as prescribed; do not stop suddenly. If you miss a dose, take it as soon as you remember unless it is close to the next dose. Do not double doses.,May take up to 4 weeks to feel full benefit. Continue medication even if you feel better.,Avoid alcohol and grapefruit juice. Grapefruit can increase Pexeva levels and side effects.,May cause drowsiness, dizziness, or blurred vision. Do not drive or operate machinery until you know how Pexeva affects you.,Report any suicidal thoughts, agitation, or worsening depression immediately to your doctor.,Common side effects include nausea, dry mouth, constipation, decreased appetite, and sexual dysfunction. These often improve over time.
Take Luvox exactly as prescribed, usually once daily at bedtime to minimize daytime drowsiness.,It may take several weeks to feel the full effect; do not stop abruptly without consulting your doctor.,Avoid grapefruit juice, which can increase Luvox levels and side effects.,Report any signs of serotonin syndrome (hallucinations, agitation, rapid heart rate, fever, muscle stiffness) immediately.,Do not drive or operate heavy machinery until you know how Luvox affects you, as it can cause drowsiness or dizziness.,Limit alcohol consumption; alcohol can worsen sedation and increase risk of side effects.,Store at room temperature, away from moisture and heat.
No interactions on record
"Tetracycline may inhibit the metabolism of Fluvoxamine via cytochrome P450 enzyme interference, leading to increased Fluvoxamine plasma concentrations. This elevation potentiates serotonergic effects and may precipitate serotonin syndrome, characterized by hyperthermia, autonomic instability, and neuromuscular abnormalities. Concurrent use requires careful monitoring for signs of toxicity such as agitation, confusion, and tachycardia."
"Dexlansoprazole, a proton pump inhibitor (PPI), may inhibit CYP1A2, the primary enzyme responsible for metabolizing fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). This interaction can lead to increased plasma concentrations of fluvoxamine, potentiating its serotonergic effects and risk of dose-dependent adverse events such as nausea, somnolence, and serotonin syndrome. Clinicians should monitor for signs of fluvoxamine toxicity and consider dose adjustment when initiating or discontinuing dexlansoprazole."
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEXEVA vs LUVOX, answered by our medical review team.
PEXEVA is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.. LUVOX is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEXEVA and LUVOX depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEXEVA is: Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).. The standard adult dose of LUVOX is: Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEXEVA and LUVOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEXEVA is classified as Category C. PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, part. LUVOX is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hype. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.